Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

COVID-19 infection and rheumatoid arthritis : Faraway, so close!

The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients

Year of Publication: 2020
Contained in: Autoimmunity reviews Vol. 19, No. 5 (2020), p. 102523
All journal articles: Search for all articles in this journal
Language: English
Contributors: Favalli, Ennio Giulio | Author
Ingegnoli, Francesca
De Lucia, Orazio
Cincinelli, Gilberto
Cimaz, Rolando
Caporali, Roberto
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Coronavirus
Cytokine release syndrome
DMARDs
Journal Article
Review
Rheumatoid arthritis
Treatment
Additional Keywords: *Betacoronavirus
*Immunocompromised Host
Antirheumatic Agents
Arthritis, Rheumatoid
China
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
ISSN: 1873-0183
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 21.04.2020
Date Revised 21.04.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32205186
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.autrev.2020.102523
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03768nma a2200757 c 4500
001 NLM308754611
003 DE-601
005 20200422215256.0
007 cr uuu---uuuuu
008 200330s2020 000 0 eng d
024 7 |a 10.1016/j.autrev.2020.102523  |2 doi 
028 5 2 |a pubmed20n1176.xml 
035 |a S1568-9972(20)30078-1 
035 |a (DE-599)NLM32205186 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Favalli, Ennio Giulio 
245 1 0 |a COVID-19 infection and rheumatoid arthritis  |h Elektronische Ressource  |b Faraway, so close! 
300 |a Online-Ressource 
500 |a Date Completed 21.04.2020 
500 |a Date Revised 21.04.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier B.V. All rights reserved. 
520 |a The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Antirheumatic Agents  |6 D018501  |a *therapeutic use  |6 Q000627 
653 2 |a Arthritis, Rheumatoid  |6 D001172  |a complications  |6 Q000150  |a *immunology  |6 Q000276  |a virology  |6 Q000821 
653 2 |a *Betacoronavirus  |6 D000073640 
653 2 |a China  |6 D002681 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Humans  |6 D006801 
653 2 |a *Immunocompromised Host  |6 D016867 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
655 7 |a COVID-19  |2 gnd 
655 7 |a Coronavirus  |2 gnd 
655 7 |a Cytokine release syndrome  |2 gnd 
655 7 |a DMARDs  |2 gnd 
655 7 |a Rheumatoid arthritis  |2 gnd 
655 7 |a Treatment  |2 gnd 
655 7 |a Antirheumatic Agents  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Coronavirus 
689 1 2 |a Cytokine release syndrome 
689 1 3 |a DMARDs 
689 1 4 |a Rheumatoid arthritis 
689 1 5 |a Treatment 
689 1 |5 DE-601 
689 2 0 |a Antirheumatic Agents 
689 2 |5 DE-601 
700 1 |a Ingegnoli, Francesca 
700 1 |a De Lucia, Orazio 
700 1 |a Cincinelli, Gilberto 
700 1 |a Cimaz, Rolando 
700 1 |a Caporali, Roberto 
773 0 8 |i in  |t Autoimmunity reviews  |g Vol. 19, No. 5 (2020), p. 102523  |q 19:5<102523  |w (DE-601)NLM126100284  |x 1873-0183 
856 4 1 |u http://dx.doi.org/10.1016/j.autrev.2020.102523  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2020  |e 5  |b 20  |c 05  |h 102523